company background image
KPRX

Kiora Pharmaceuticals NasdaqCM:KPRX Stock Report

Last Price

US$3.28

Market Cap

US$5.6m

7D

-7.1%

1Y

-88.0%

Updated

07 Feb, 2023

Data

Company Financials +

Kiora Pharmaceuticals, Inc.

NasdaqCM:KPRX Stock Report

Mkt Cap: US$5.6m

KPRX Stock Overview

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States.

KPRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Kiora Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kiora Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.28
52 Week HighUS$39.18
52 Week LowUS$2.32
Beta0.27
1 Month Change-11.35%
3 Month Change-44.31%
1 Year Change-88.01%
3 Year Change-98.81%
5 Year Change-99.20%
Change since IPO-99.90%

Recent News & Updates

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Kiora Pharma announces 1-for-40 reverse stock split

Sep 26

Recent updates

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Kiora Pharma announces 1-for-40 reverse stock split

Sep 26

Kiora Pharmaceuticals reports 1H results

Aug 12

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Jul 28

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Jul 22

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Jul 05

EyeGate Pharmaceuticals announces $8M private placement

Jan 06

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Dec 21

Shareholder Returns

KPRXUS PharmaceuticalsUS Market
7D-7.1%-0.7%0.9%
1Y-88.0%4.9%-10.9%

Return vs Industry: KPRX underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.

Return vs Market: KPRX underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is KPRX's price volatile compared to industry and market?
KPRX volatility
KPRX Average Weekly Movement19.0%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: KPRX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: KPRX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199814Brian Stremhttps://www.kiorapharma.com

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery.

Kiora Pharmaceuticals, Inc. Fundamentals Summary

How do Kiora Pharmaceuticals's earnings and revenue compare to its market cap?
KPRX fundamental statistics
Market CapUS$5.59m
Earnings (TTM)-US$17.27m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KPRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$5.04m
Gross Profit-US$5.04m
Other ExpensesUS$12.23m
Earnings-US$17.27m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-10.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did KPRX perform over the long term?

See historical performance and comparison